Influenza Hemagglutinin (HA) Peptide: Precision Epitope Tag for Protein Purification

Executive Summary: The Influenza Hemagglutinin (HA) Peptide (sequence: YPYDVPDYA) is a universally adopted molecular tag for detection and purification of recombinant proteins, enabling high-affinity interaction with anti-HA antibodies for immunoprecipitation workflows (APExBIO, A6004 product page). Its solubility exceeds 55 mg/mL in DMSO, 100 mg/mL in ethanol, and 46 mg/mL in water, supporting diverse buffer requirements. The tag's utility is grounded in reproducible, high-purity synthesis (>98%, HPLC and MS-verified). The HA tag is essential for competitive elution of fusion proteins during antibody-based purification (Dong et al., 2025). APExBIO’s HA Peptide is validated for use in advanced protein interaction, ubiquitination, and mechanistic cancer studies.

Biological Rationale

The HA tag is derived from the epitope region of the influenza virus hemagglutinin protein, specifically residues 98–106 (YPYDVPDYA). This short peptide is not naturally present in mammalian proteomes, minimizing background in detection assays. The HA epitope tag enables specific recognition by monoclonal and polyclonal anti-HA antibodies, facilitating immunoprecipitation, Western blotting, and protein localization (see mechanistic insights here). The tag’s function parallels other epitope tags, such as FLAG and Myc, but is distinguished by its low immunogenicity and robust antibody availability. In cancer research, epitope tagging is critical for studying protein-protein interactions, ubiquitination events, and pathway modulation, as exemplified by recent metastasis inhibition studies (Dong et al., 2025).

Mechanism of Action of Influenza Hemagglutinin (HA) Peptide

The HA peptide operates as a competitive ligand for anti-HA antibodies. When fused to recombinant proteins, it enables selective capture on antibody-coated matrices—such as magnetic beads or agarose. Free HA peptide (synthetic, e.g., APExBIO A6004) can then be added to elute the tagged protein by outcompeting bead-bound interactions. This mechanism is central to immunoprecipitation and pull-down assays, allowing for high specificity and gentle elution conditions (typically neutral pH, 4°C). The HA peptide’s solubility profile (≥55.1 mg/mL in DMSO, ≥100.4 mg/mL in ethanol, ≥46.2 mg/mL in water) permits its use in a wide range of experimental buffers and concentrations (APExBIO). High purity (>98%) ensures minimal cross-reactivity or interference in downstream analyses.

Evidence & Benchmarks

• HA peptide enables highly specific immunoprecipitation of HA-tagged proteins using anti-HA antibodies, with competitive elution confirmed in multiple cancer and signaling pathway studies (Dong et al., 2025).
• Solubility benchmarks for the APExBIO A6004 peptide: ≥55.1 mg/mL in DMSO, ≥100.4 mg/mL in ethanol, and ≥46.2 mg/mL in water at ambient temperature, supporting flexible protocol design (product data).
• Peptide identity and purity (>98%) are validated by high-performance liquid chromatography (HPLC) and mass spectrometry, ensuring reproducibility in quantitative workflows (see benchmarks extension).
• Epitope tagging with HA does not interfere with the majority of mammalian protein functions and is suitable for both N-terminal and C-terminal fusions (further protocol insights).
• APExBIO’s HA peptide supports antibody-based detection in both Western blot and immunofluorescence contexts, with minimal off-target binding (expanded detection scope).

Applications, Limits & Misconceptions

The Influenza Hemagglutinin (HA) Peptide is extensively used as a protein purification tag, an epitope tag for protein detection, and a competitive elution agent in immunoprecipitation assays. Its high specificity is harnessed in the study of protein-protein interactions, post-translational modifications (such as ubiquitination involving E3 ligases like NEDD4L), and translational research in cancer metastasis (Dong et al., 2025). In comparison to other tags, the HA peptide exhibits superior solubility and compatibility with antibody-based workflows. This article extends the in-depth mechanistic framework established in this mechanistic insight article by providing quantitative benchmarks and workflow-specific guidance.

Common Pitfalls or Misconceptions

• The HA peptide does not facilitate direct cell entry—tagging must be genetically engineered into the target protein.
• Elution efficiency depends on proper optimization of peptide concentration and buffer conditions; suboptimal parameters reduce recovery.
• Cross-reactivity may occur if anti-HA antibodies are not validated for the species or application (e.g., Western blot vs. IP).
• Long-term storage of peptide solutions is not recommended; lyophilized peptide should be stored desiccated at -20°C for stability.
• Not all proteins preserve function after HA-tag fusion; empirical validation is required for each construct.

Workflow Integration & Parameters

To utilize the Influenza Hemagglutinin (HA) Peptide in immunoprecipitation or protein purification workflows, fusion constructs are generated by cloning the HA tag at the N- or C-terminus of the protein coding sequence. Anti-HA antibody-conjugated beads capture the tagged protein from lysate. Elution is achieved by adding synthetic HA peptide at concentrations of 1–3 mg/mL in PBS or Tris-buffered saline, typically at 4°C for 15–30 minutes. The recommended storage for the APExBIO A6004 peptide is -20°C, desiccated; avoid repeated freeze-thaw cycles and prolonged solution storage. Detailed troubleshooting and advanced protocol enhancements are discussed in this workflow-focused article, which this review updates with recent solubility and purity metrics.

For comprehensive application benchmarking and troubleshooting, see our comparative benchmarks article, which this review builds upon by integrating the latest cancer signaling research and purity data.

Conclusion & Outlook

The Influenza Hemagglutinin (HA) Peptide remains the gold standard for precise, antibody-mediated detection and purification of fusion proteins in molecular biology and translational research. APExBIO’s A6004 peptide combines validated purity, solubility, and functional reliability, supporting advanced studies in ubiquitination, protein interaction, and mechanistic cancer biology. Continued integration with evolving immunoprecipitation technologies and mechanistic cancer models will further expand its utility. For full technical specifications and ordering, visit the product page.